Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 13

What is the impact of GOLD 2017 recommendations in primary care? – a descriptive study of patient classifications, treatment burden and costs

Authors Gayle A, Dickinson S, Morris K, Poole C, Mathioudakis AG, Vestbo J

Received 10 May 2018

Accepted for publication 23 July 2018

Published 23 October 2018 Volume 2018:13 Pages 3485—3492

DOI https://doi.org/10.2147/COPD.S173664

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Richard Russell


Alicia Gayle,1 Scott Dickinson,2 Kevin Morris,1 Chris Poole,1 Alexander G Mathioudakis,3 Jørgen Vestbo3,4

1Market Access, Boehringer Ingelheim Ltd, Bracknell, UK; 2Medical and Scientific Affairs, Boehringer Ingelheim Ltd, Bracknell, UK; 3Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK; 4Manchester Academic Health Sciences Centre, Manchester University NHS Foundation Trust, Manchester, UK

Purpose: The changes in grading of disease severity and treatment recommendations for patients with COPD in the 2017 GOLD strategy may present an opportunity for reducing treatment burden for the patients and costs to the health care system. The aim of this study was to assess the implications of the GOLD 2017 grading system in terms of change in distribution across GOLD groups A–D for existing patients in UK primary care and estimate the potential cost savings of implementing GOLD 2017 treatment recommendations in UK primary care.
Patients and methods: Using electronic health record data from the Clinical Practice Research Datalink (CPRD), patients aged ≥35 years with spirometry-confirmed COPD, receiving care during 2016, were included. The cohort was graded according to the GOLD 2017 groups (A–D), and treatment costs were calculated, according to corresponding recommendations, to observe the difference in actual vs predicted costs.
Results: When applying GOLD 2013 criteria, less than half of the cohort (46%) was assigned to GOLD A or B, as compared to 86% when applying the GOLD 2017 grading. The actual mean annual maintenance treatment cost was £542 per patient vs a predicted £389 for treatment according to the 2017 GOLD strategy.
Conclusion: There is a potential to make significant cost savings by implementing the grading and treatment recommendations from the 2017 GOLD strategy.

Keywords: COPD, GOLD, severity, economics

Erratum for this paper has been published.

 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]